In addition, other studies suggested that the absolute number of activated NK cells was higher in BC patients who achieved pathological complete responses (PCR) after neoadjuvant chemotherapy, which implied that the improvement of NK cell activities was essential requirement for pCR especially in HER2-positive BC patients (79, 80). This evidence concerns the gene ERBB2 and breast cancer.